Pituitary FSH Content Research Articles

Characterization of a novel fast-growing zebrafish: a new approach to growth hormone transgenesis.

The manipulation of the somatotropic axis, governing growth, has been a focus of numerous transgenic approaches aimed at developing fast-growing fish for research, medicine and aquaculture purposes. However, the excessively high growth hormone (GH) levels in these transgenic fish often result in deformities that impact both fish health and consumer acceptance. In an effort to mitigate these issues and synchronize exogenous GH expression with reproductive processes, we employed a novel transgenic construct driven by a tilapia luteinizing hormone (LH) promoter. This approach was anticipated to induce more localized and lower exogenous GH secretion. In this study, we characterized the growth and reproduction of these transgenic LHp-GH zebrafish using hormonal and physiological parameters. Our findings reveal that LHp-GH fish exhibited accelerated growth in both length and weight, along with a lower feed conversion ratio, indicating more efficient feed utilization, all while maintaining unchanged body proportions. These fish demonstrated higher expression levels of LH and GH in the pituitary and elevated IGF-1 levels in the liver compared to wild-type fish. An examination of reproductive function in LHp-GH fish unveiled lower pituitary LH and FSH contents, smaller follicle diameter in female gonads, and reduced relative fecundity. However, in transgenic males, neither the distribution of spermatogenesis stages nor sperm concentrations differed significantly between the fish lines. These results suggest that coupling exogenous GH expression with endogenous LH expression in females directs resource investment toward somatic growth at the expense of reproductive processes. Consequently, we conclude that incorporating GH under the LH promoter represents a suitable construct for the genetic engineering of commercial fish species, providing accelerated growth while preserving body proportions.

Differential action of androgen implants on the spermatogenesis of pre-pubertal sea bass exposed to a continuous light regime

This study investigated the influence of long-term T and 11-KT administration (by means of an implant) on the synthesis and release of gonadotropins (Fsh, Lh) and spermatogenesis progression in juvenile male sea bass exposed to either a natural photoperiod (NP) or continuous light (LL). The results in the control group indicated a clear role for Fsh and 11-KT in the recruitment of type-A spermatogonia (SPGA) towards more advanced stages of spermatogenesis under the NP regime. Fsh promoted androgen synthesis and SPGA differentiation into spermatocytes, while no significant changes in pituitary Gnrh1 and plasma Lh levels were detected. On the other hand, the LL regime inhibited Fsh synthesis, and although no effects were observed on Gnrh1 and Lh, the progression of spermatogenesis was arrested. T and 11-KT administration increased the Gnrh1 and Lh content and reduced the pituitary Fsh content, regardless of the photoperiod regime, although the inhibitory effect of T on pituitary Fsh was stronger than that of 11-KT. Our results show that exogenous 11-KT administration in fish under the LL regime was able to partially restore the progression of spermatogenesis, thus stimulating gonadal development and eliciting spermiation in a few fish, while males that received T implants remained sexually immature under LL. In addition, our results provided new knowledge about the importance of Fsh bioactivity modulation in the regulation of this gonadotropin function, and in turn, on spermatogenesis control in fish.

OR24-3 Persistence of Progenitor Cell Markers Following the Selective Ablation of Musashi in Somatotropes

Metabolic and reproductive demands are met and coordinated through the complex control of hormone synthesis and secretion exerted by the anterior pituitary. While pituitary cells are known to possess remarkable plasticity to change their cell fate and alter hormone production in response to ever changing environmental cues, the underlying molecular control of this plasticity has not been established. Our lab has previously introduced the Musashi (MSI) family of RNA binding proteins as important players in control of pituitary hormone levels. Musashi typically governs stem cell fate and promotes self-renewal by repressing translation of target mRNAs needed for differentiation. However, we found that MSI1 is expressed in most differentiated cells of the adult pituitary and can specifically bind to the 3’ UTRs of Prl, Tsh, and Pou1f1 and exert translational control in reporter assays. Confirmation of the requirement for MSI was demonstrated through in vivo analyses where MSI1 and MSI2 were selectively ablated in somatotropes. The mutant animals were subfertile. The mutant males showed reduced serum and pituitary content of LH and FSH, and significant decreases in serum GH and PRL despite 2-fold increases in pituitary protein content of PRL and GH. To further assess the role and downstream pathways regulated by MSI in the pituitary, we collected somatotrope MSI-null pituitaries from males and females for qPCR analysis of common somatotrope target genes. In correlation with our previous findings described above (low serum GH and high pituitary GH content), we found that GHRHR mRNA levels were reduced by 2-fold in male mutants. RNA-seq analysis followed by qPCR validation shows that Prop1 mRNA was significantly increased in male mutants, with no significant change in Pou1f1 mRNA. These data suggest that MSI may be involved in the regulation of progenitor cells giving rise to the somatotrope lineage and that MSI ablation may have caused retention of these progenitors and/or a failure to fully differentiate somatotropes. Our studies of MSI-null somatotrope function support this interpretation because the mutant somatotropes clearly stored GH proteins, but could not secrete them, as demonstrated by the low serum GH values, and the 50% reduction in GHRHR mRNA. RNA-seq evaluation of males revealed a change in the expression of 720 genes between controls and mutants (FDR <0.05). When we examined female MSI-null somatotrope animals, a much smaller cohort of genes showed a change in expression (153 genes, FDR <0.05). Interestingly, 38 genes were altered in both mutant males and females suggesting shared regulation by MSI. Further characterization of the NGS datasets will elucidate additional downstream targets and effector pathways of MSI-dependent control of anterior pituitary cell differentiation and function.

Endocrine and reproductive responses of male and female cattle to agonists of gonadotrophin-releasing hormone

The pituitary response in cattle to treatment with GnRH agonist has two phases. In the acute phase secretion of LH is increased, while the chronic phase is characterized by a downregulation of GnRH receptors and insensitivity of gonadotrophs to natural sequence GnRH. After long-term treatment with GnRH agonist, cattle do not have pulsatile secretion of LH but maintain basal LH. This is associated with reduced pituitary contents of LH, LH mRNA, FSH and FSH mRNA. Long-term treatment of bulls with GnRH agonist results in an increase in testicular LH receptors and high plasma testosterone. Heifers treated with a GnRH agonist from early in the oestrous cycle develop a larger corpus luteum and secrete more progesterone. Increased steroidogenesis is reflected in increased steroid acute regulatory (StAR) protein and steroidogenic enzymes in the testes and corpus luteum. GnRH agonists have potential as novel strategies for reproductive management in cattle. A GnRH agonist bioimplant was recently used to block the LH surge after FSH stimulation of follicle growth in heifers. Ovulation was induced by injection of LH, and heifers were inseminated relative to the LH injection. This GnRH agonist-LH protocol provides a model for studying the gonadotrophin requirements for follicular growth and oocyte maturation in cattle, and will enable controlled in vivo maturation of oocytes before recovery for in vitro procedures.

Mechanism of action of endosulfan as disruptor of gonadal steroidogenesis in the cichlid fish Cichlasoma dimerus

The organochlorine pesticide endosulfan (ES) is used in several countries as a wide spectrum insecticide on crops with high commercial value. Due to its high toxicity to non-target animals, its persistence in the environment and its ability to act as an endocrine disrupting compound in fish, ES use is currently banned or restricted in many other countries. Previous studies on the cichlid fish Cichlasoma dimerus have shown that waterborne exposure to ES can lead to both decreased pituitary FSH content and histological alterations of testes. As gonadotropin-stimulated sex steroids release from gonads was inhibited by ES in vitro, the aim of the present study was to elucidate possible mechanisms of disruption of ES on gonadal steroidogenesis in C. dimerus, as well as compare the action of the active ingredient (AI) with that of currently used commercial formulations (CF). Testis and ovary fragments were incubated with ES (AI or CF) and/or steroidogenesis activators or precursors. Testosterone and estradiol levels were measured in the incubation media. By itself, ES did not affect hormone levels. Co-incubation with LH and the adenylate cyclase activator forskolin caused a decrease of the stimulated sex steroids release. When co-incubated with precursors dehydroandrostenedione and 17αhydroxyprogesterone, ES did not affect the increase caused by their addition alone. No differences were observed between the AI and CFs, suggesting that the effect on steroidogenesis disruption is mainly caused by the AI. Results indicate that action of ES takes place downstream of LH-receptor activation and upstream of the studied steroidogenic enzymes.

Effects of immunization against luteinizing hormone-releasing hormone and treatment with trenbolone acetate on reproductive function of beef bulls and steers1

The objectives of this study were 1) to evaluate the ability of trenbolone acetate (TBA) administered in tandem with LHRH immunization to suppress reproductive function in bulls and 2) to examine the effects of LHRH and androgen (TBA) signaling on pituitary gland function. Forty-four Angus × Hereford crossbred calves (BW=225 ± 2 kg; age=187 ± 6 d) received castration, LHRH immunization, or TBA administration in a 2 × 2 × 2 factorial design. Treatment groups receiving LHRH immunization contained 6 animals, whereas other treatment groups contained 5 animals. Animals immunized against LHRH received a primary injection and 2 booster injections of ovalbumin-LHRH-7 fusion protein on d 0, 42, and 196, respectively. Animals treated with TBA were implanted on d 224. Serum LHRH antibodies increased (P<0.05) after each booster for immunized animals, but were negligible in nonimmunized animals throughout the experiment. Serum testosterone concentration (P<0.001) and scrotal circumference (P<0.05) were depressed in LHRH-immunized bulls compared with nonimmunized bulls by d 84 and 168 of the experiment, respectively. Treatment with TBA tended (P=0.08) to decrease serum testosterone concentrations of nonimmunized bulls. Weights of testes at slaughter were decreased (P<0.001) for LHRH-immunized (232 ± 41 g) compared with nonimmunized (752 ± 45 g) bulls, but did not differ (P=0.80) between TBA-implanted (500 ± 49 g) and nonimplanted bulls (484 ± 36 g). Both LHRH immunization and castration decreased pituitary gland stores of LH and FSH (P<0. 001). There was no effect (P>0.10) of TBA on pituitary gland FSH content and only a tendency (P=0.09) to increase pituitary gland LH content. Immunization against LHRH decreased expression of LH β-subunit and common α-subunit genes (P<0.001). Castration increased expression of LH β-subunit and common α-subunit genes (P=0.02). Treatment with TBA further suppressed (P=0.04) α-subunit mRNA expression in LHRH-immunized steers. In summary, LHRH immunization decreased synthesis and storage of LH and decreased storage, but not synthesis of FSH in bulls. The increased synthesis of LH and FSH in nonimmunized, but not LHRH-immunized steers suggests that castration removes the negative feedback on gonadotropin synthesis but that LHRH is still needed for release of these hormones. Androgen replacement with TBA did not restore the negative feedback control of gonadotropin synthesis.

Plasma and pituitary gonadotropins and prolactin after hysterectomy and treatment with uterine extracts in female rats. A kinetic study.

The kinetic of changes in plasma concentrations and pituitary contents of FSH, LH, prolactin after hysterectomy and treatment with steroid-free uterine extracts were studied in adult, non-pregnant female rats. The post-castration rise of plasma and pituitary FSH and plasma LH was inhibited but the plasma prolactin was elevated by hysterectomy. Steroid-free uterine extracts from previously castrated animals increased the plasma FSH, LH and prolactin concentrations in hysterectomized females 48 hours after administration. Uterine extracts from intact and oestradiol-substituted-castrated animals decreased the pituitary prolactin content 48 h after single i.p. injection. Pituitary FSH and LH contents were not affected by single dose of uterine extracts at any time which were examined. It is concluded that the uterus may play some role in the synthesis and release of pituitary gonadotropins and prolactin.

Effects of hysterectomy and uterine extracts on the gonadotrophic hormones and the weight of endocrine organs of female rats.

The previous observation that hysterectomy of rats results in increased pituitary nucleic acid turnover was followed up by studies on pituitary function in hysterectomized adult female rats with or without treatment with charcoal-treated crude uterine aqueous extracts. Hysterectomy had no effect on the pituitary or plasma LH and FSH concentrations. Administration of crude uterine extracts diminished the post-castrational rise of the pituitary FSH content without affecting the plasma FSH or LH concentrations. Hysterectomy decreased body weight but increased adrenal weight of ovariectomized animals. However, the body weight and pituitary weight of both the intact and ovariectomized animals increased significantly following 14 days of treatment with uterine extracts. The ovarian weight of the intact rats was reduced by this treatment. The pituitary nucleic acid content of castrated but oestradiol-substituted rats was reduced by hysterectomy. Plasma corticosterone concentrations were not affected by the above mentioned treatments. Uterine extracts inhibited the basal and GnRH induced LH release from isolated pituitary cells in culture. The effects of hysterectomy and/or administration of crude uterine aqueous extracts show that the uterus contains biologically active, non-steroidal substances which affect pituitary function of adult female rats.

Relationship between serum gonadotropins and pituitary immunoreactive gonadotropins and steroid receptors during the first FSH increase of the estrous cycle and following steroid treatment in heifers

The objectives were to determine the effects of (i) time during the first FSH increase of the estrous cycle (time-course study) and (ii) exogenous steroid treatment (steroid feedback study) on the relationship between circulating serum gonadotropins, and the proportions of pituitary cells immunoreactive for gonadotropins and steroid receptors during the estrous cycle in heifers. Pituitaries were collected from heifers ( n = 40) slaughtered at 13 h ( n = 8), 30 h ( n = 24) and 66 h ( n = 8) after estrous onset, corresponding to before, during and after the first FSH increase of the estrous cycle. Heifers slaughtered during the FSH increase (at 30 h) either received no treatment ( n = 8), or were treated ( n = 16) with estradiol benzoate and/or progesterone before slaughter. During the time-course study, the proportion of pituitary cells immunoreactive for FSH increased ( P < 0.05) during the first transient FSH increase reflecting serum concentrations. The proportion of pituitary cells immunoreactive for LH was unaltered, a reflection of serum LH concentrations. The proportion of estrogen receptors (ER)-α, but not ER-β, was decreased ( P < 0.05) at 30 h compared with at either 13 or 66 h. During the steroid feedback study, exogenous progesterone with or without estradiol suppressed ( P < 0.05) the proportions of pituitary cells immunoreactive for gonadotropins, serum FSH concentrations and LH pulse frequency. Steroid treatment did not alter the proportion of pituitary cells positive for estrogen receptors (α and β). While progesterone receptors (PR) were not detected in the anterior pituitary by immunohistochemistry during the early estrous cycle or in response to steroid treatment, quantitative real-time PCR revealed that mRNA for progesterone receptors was expressed at very low levels. The expression of pituitary PR mRNA was decreased ( P < 0.05) at 30 and 66 h compared with 13 h, and was suppressed ( P < 0.05) following steroid treatments. Alterations in pituitary steroid receptors are implicated in the differential regulation of gonadotropin secretion during the first transient FSH rise, but not in response to exogenous steroids. The time-course study and steroid feedback responses support the hypothesis that LH pulse frequency is tightly linked to regulation of GnRH pulse frequency. Serum FSH is regulated by its own synthesis, as reflected by pituitary FSH content and perhaps by alterations in pituitary sensitivity to circulating steroids by changes in steroid receptor content.

High prevalence rate of pituitary incidentaloma: Is it associated with the age-related decline of the sex hormones levels?

Incidental pituitary adenoma is the common finding during brain imaging. According to multistep model of pituitary tumourigenesis genetic alterations provide the initiating event that transforms cells while hormones play a role in promoting cell proliferation. Development of pituitary adenoma in a case of excessive hypophysiotrophic hormones production or reduced feedback suppression by target gland hormones emphasizes the importance of hormonal stimulation in pituitary tumourigenesis. Pituitary hyperplasia has been reported in pregnancy, hypothyroidism and conditions such as CRH or GHRH hypersecretion. Moreover, recent study reported one case of gonadotroph macroadenoma and two cases of gonadotroph cells hyperplasia in patients with Klinefelter syndrome probably due to protracted stimulation of gonadotroph cells because of lack of androgen feedback. Significant changes of the hypothalamic-pituitary-gonadal axis occurred with aging. In females, after menopause, estradiol level decreases by 35-fold and estrone level by 20-fold that results in increased gonadotropins levels. Similarly, FSH, but not LH, level is increased with advancing age in men, too, although the age-related difference in the level is less in comparison with women. Regarding these data, we hypothesised that high prevalence rate of pituitary incidentaloma in the elderly is associated with age-related decline in sex hormones levels and subsequent lack of feedback suppression leading to permanent gonadotrophs stimulation which is the crucial step in the pituitary tumour development. According to previously mentioned multistep model of pituitary tumourigenesis, incidentaloma will develop only in persons with already present intrinsic pituitary cell defects. However, further studies have to answer the questions of whether the incidence of pituitary tumours is more frequent in elderly, whether women with late onset menopause or those taking long-term hormone replacement therapy have lower rate of pituitary incidentaloma, and finally, is there any correlation between pituitary tumours incidence and serum concentrations of LH, FSH, bioavailable testosterone or estradiol.

Influence of short-term fasting during the luteal phase of the estrous cycle on ovarian follicular development during the ensuing proestrus of ewes

Short-term fasting of mature ewes during diestrus results in increased serum concentrations of progesterone and a delayed pre-ovulatory surge release of LH. To determine if these changes in reproductive hormones influence subsequent follicular development, mature ewes observed in estrus were assigned randomly to control ( n = 10) or fasted ( n = 15) groups. Control ewes had ad libitium access to feed, whereas fasted ewes were not fed from day 7 through 11 of their estrous cycle. Daily blood samples were collected from control and fasted ewes throughout the fasting period. Fasting increased ( P < 0.001) serum concentrations of progesterone (4.4 ng/mL versus 2.7 ng/mL [±0.3]). On day 12, all ewes were treated with 10 mg of PGF 2α and fasted ewes were returned to ad libitum feed. Ovaries were collected from ewes ( n = 5 each group) at 0 and 72 h following PGF 2α in control and 0, 72 and 96 h in fasted ewes. Ovaries were weighed and small (≤2 mm), medium (3–4 mm), and large (≥5 mm) follicles were enumerated. Total numbers of follicles were less ( P < 0.001) in fasted than fed ewes (14.6 versus 30.2 [±2.2]) at 0 h, but did not differ ( P = 0.9) when numbers of follicles were compared at similar times before the anticipated LH surge (i.e., at 72 h versus 96 h in control and fasted ewes, respectively). Within follicular size class, numbers of small and medium follicles were decreased ( P = 0.04) at 0 h in fasted ewes. Numbers of large follicles did not differ ( P = 1.0) between groups. Although numbers of small and medium ovarian follicles in fasted ewes recovered by 96 h to values comparable to fed ewes at 72 h following PGF 2α, serum concentrations of estradiol 17β ( P = 0.08) and FSH ( P = 0.06) tended to be decreased in fasted ewes before the anticipated surge release of LH. Pituitary content of LH and FSH also tended to be lower ( P ≤ 0.09) at 96 h in fasted ewes than at 72 h in control ewes, but did not differ ( P ≥ 0.4) at hour 0 following PGF 2α. Hypothalamic and stalk median eminence contents of GnRH were not influenced ( P ≥ 0.2) by fasting at any time period. Fasting during the luteal phase perturbs gonadotropin secretion and may influence fertility by causing a delay in ovarian follicle development.

The hypogonadal (hpg) mouse as a model to investigate the estrogenic regulation of spermatogenesis

The hypogonadal (hpg) mouse is an excellent animal model in which to investigate the mechanism of action of estrogens on spermatogenesis because it has arrested reproductive development without the need for surgical, endocrine, pharmacological or immunological intervention. Hpg mice are hypogonadotrophic and fail to show normal postnatal testicular development due to the congenital inability to synthesize gonadotropin-releasing hormone in the hypothalamus. The hpg testis remains responsive to gonadotropins and androgens in that fertility can be induced by treatment with these hormones. Surprisingly, chronic treatment with low concentrations of estradiol alone induces qualitatively normal spermatogenesis. The induction of testicular development by estradiol in hpg mice is accompanied by a paradoxical increase in FSH production. The actions of estradiol in hpg mice appear to be via genomic estrogen receptors, as concurrent treatment with estrogen-receptor antagonist ICI182,780 completely blocks these pituitary and testis responses. Concurrent treatment with the androgen receptor antagonist bicalutamide does not affect the estradiol-induced increase in pituitary FSH content, but markedly attenuates the estradiol-induced increase in testicular weight. Western blot analyses and immunohistochemistry provide evidence for estrogen-receptor α and β expression in both pituitary gland and testis of the hpg mouse. Estradiol may therefore exert direct actions within the testes and/or indirect neuroendocrine actions via the release of FSH or other hormones from the pituitary gland, but its actions are dependent upon the availability of low levels of androgen within the testis.

Estrogenic induction of spermatogenesis in the hypogonadal (hpg) mouse: role of androgens

Testicular development is arrested in the hypogonadal (hpg) mouse due to a congenital deficiency of hypothalamic gonadotropin-releasing hormone synthesis. Previous studies have demonstrated that chronic treatment of these mice with estradiol induces testicular maturation and qualitatively normal spermatogenesis, but it is not known whether these are direct effects via estrogen receptors expressed in the testis, or indirect actions via the pituitary gland. The aim of the current studies was to determine whether the actions of estradiol require the presence of androgens. Sensitive assays revealed that chronic estradiol treatment produced time-dependent increases in pituitary FSH production but no increases in pituitary LH or testicular testosterone content could be detected. As a functional test of androgen dependence, hpg mice were treated for 70 days with estradiol plus Casodex (bicalutamide), an androgen receptor antagonist. Casodex treatment markedly attenuated both the estradiol-induced increase in testicular weight and the proliferation of the seminiferous epithelium, as revealed by morphometric analysis. However, it did not affect the estradiol-induced increase in pituitary FSH content, nor did it affect estradiol-induced increases in the weight of the seminal vesicles and epididymides. We conclude that increased FSH production is not sufficient to explain the increase in testicular development induced by estradiol in hpg mice; there is a requirement for functional androgen receptors for induction of testicular growth.

Neonatal androgenization of hypogonadal (hpg) male mice does not abolish estradiol-induced FSH production and spermatogenesis

BackgroundTesticular development is arrested in the hypogonadal (hpg) mouse due to a congenital deficiency in hypothalamic gonadotropin-releasing hormone (GnRH) synthesis. Chronic treatment of male hpg mice with estradiol induces FSH synthesis and secretion, and causes testicular maturation and qualitatively normal spermatogenesis. As estradiol negative feedback normally inhibits FSH production in the male, this study tested whether this paradoxical response to estradiol in the male hpg mouse might be due to inadequate masculinisation or incomplete defeminization in the neonatal period. Previous studies have demonstrated that treatment of hpg mice with testosterone propionate in the immediate neonatal period is necessary to allow full reproductive behaviors to be expressed following suitable endocrine stimulation at adult ages.MethodsHpg mice were treated with 100 μg testosterone propionate or vehicle on postnatal day 2. At 35 days of age, subgroups of these mice were treated with silastic implants containing estradiol or cholesterol. Reproductive behavior was scored in tests with steroid-primed female mice, then testicular development was assessed histologically, and measures of pituitary FSH content made at 85 days of age.ResultsThe neonatal testosterone propionate treatment successfully defeminized female litter mates, as revealed by impaired vaginal opening and deficiencies in lordosis behavior, and it allowed appropriate male reproductive behavior to be expressed in a proportion of the hpg males when tested at an adult age. However, neonatal androgen supplementation did not block or even reduce the subsequent actions of estradiol in increasing pituitary FSH content, nor did it affect the ability of estradiol to induce qualitatively normal spermatogenesis.ConclusionThe ability of the hpg male to show a "female" neuroendocrine response to estradiol is not a result of inadequate androgenization during neonatal development, and thus the actions of estradiol revealed in this rodent model are not an artefact of incomplete sexual differentiation, but reflect a physiological role of estradiol occurring during a specific early temporal window of male reproductive development.

Atrial natriuretic peptide inhibits ovarian functions in female mice

Objective: To investigate the effects of atrial natriuretic peptide (ANP) on ovarian regulation in mice through intraperitoneal administration. Study design: Forty-two ICR strain female mice were divided into seven groups, including one control. Each mouse received ovarian hyperstimulation. ANP was prepared with saline at concentrations of 0 (as control), 2, 4, 8, 10, 20, and 30 ng/g of body weight. The solution was intraperitoneally applied to each referred group ( n = 6) 1 h before the hMG and hCG injections. The mice were sacrificed next morning and blood samples were collected for analysis. Results: A significant reduction in both ovarian weight and the number of oocytes was found as the ANP dosage increased. ANP treatment decreased both serum estradiol and progesterone levels. The pituitary FSH and LH contents elevated significantly by ANP at a dosage larger than 4 ng/g of body weight; however, both serum FSH and LH levels remained unchanged. Histologically, there were remarkable ovarian inhibitory features, i.e. reduction in size and number of follicles, arrest of follicular growth and diminution of ovulation. Conclusion: Intraperitoneal administration of ANP inhibits the follicular growth, ovulation and steroidogenesis in female mice. These effects are attributed to the direct action of ANP on ovaries.

Oestradiol-17β responsiveness, plasma LH profiles, pituitary LH and FSH concentrations in long-term ovariectomised Holstein cows at 24 h, 48 h and 21 days following treatment with an absorbable GnRH agonist implant

Non-lactating OVX Holstein cows ( N = 34) were used to investigate the effect of s.c. placement of an absorbable GnRH agonist implant (Ovuplant ®; deslorelin 2.1 mg, Peptech Animal Health, Australia) on the relationship of plasma LH, oestradiol responsiveness and pituitary LH content. On the day of implant insertion (Day 0), one group (OVU-48h; N = 5) received Ovuplant ® and had blood samples collected at hourly intervals to characterize the LH response, while a second group (CON-48h; N = 5) remained untreated and acted as controls. Blood samples were collected every 10 min over 6 h from CON-48h and OVU-48h, at 24 h post-implant insertion. These cows were then slaughtered at 48 h post-implant insertion and their pituitaries recovered. Another group received Ovuplant ® (OVU-21d+E2; N = 10) or were left untreated (CON-21d+E2) and 21 days later were injected i.m. with 0.5 mg 17β-E2. Blood samples were collected every 10 min for 4 h on the day before E2 injection to characterize LH pulse frequency and amplitude. Beginning 14 h later, blood samples were collected hourly for 12 h to characterize the expected LH surge. These cows were slaughtered and their pituitary glands recovered and assayed for LH and FSH content. Peak plasma LH concentrations (59±19 ng/ml) were measured after 30 min of Ovuplant ® insertion. They had returned to pre-treatment levels by 7 h. By 24 h post-implant insertion, OVU-48h plasma LH profiles were characterized by reduced LH pulse frequency (0.23 ± 0.09 pulses/h versus 0.75 ± 0.26 pulses/h; OVU-48h versus CON-48h; P < 0.05). The cows that received Ovuplant ® had lower LH pulse amplitude, LH pulse frequency and mean LH concentrations after 20 days. Injection of 0.5 mg 17β-E2 induced an LH surge in every one of the control cows with their peak concentrations measured 18 h post injection. No increase in LH was detected in any Ovuplant ® treated cows. Pituitary FSH content was reduced in Ovuplant ® treated cows after 48 h, but not that of LH. In conclusion, absorbable deslorelin implants induced a substantial but temporary release of LH, but even 21 days later their LH profiles were characterized by marked suppression of pulsatile LH and an absence of response to E2. These results suggest the implant has prolonged biological activity.

Effect of increasing levels of undegradable intake protein on metabolic and endocrine factors in estrous cycling beef heifers.

To determine the influence of three levels of undegradable intake protein (UIP) supplementation on metabolic and endocrine factors that influence reproduction, 23 yearling crossbred heifers (body condition score = 4.5 +/- 0.5; initial BW = 362 +/- 12 kg) were stratified by BW and assigned randomly to one of three supplements: 1) low UIP (1,135 g x heifer(-1) x d(-1); 30% CP, 115 g UIP, n = 7); 2) mid UIP (1,135 g x heifer(-1) x d(-1); 38% CP, 216 g UIP, n = 8); or 3) high UIP (1,135 g x heifer(-1) x d(-1); 46% CP, 321 g UIP, n = 8). Heifers were estrually synchronized before initiation of supplementation. Supplement was individually fed daily for 30 to 32 d, at which time heifers were slaughtered (d 12 to 14 of the estrous cycle) and tissues collected. Heifers were fed a basal diet of sudan grass hay (6.0% CP) ad libitum. On d 28 of supplementation (d 10 of the estrous cycle), no differences were observed (P > 0.10) in serum insulin or IGF-I among treatments. At slaughter (d 10 to 12 of the estrous cycle), treatments did not influence corpus luteum weight, cerebral spinal fluid leptin, or IGFBP; serum estradiol-17beta, progesterone, leptin, IGF-I, and IGFBP; or anterior pituitary content of IGFBP (P > 0.10). Follicular fluid IGFBP-2 and IGFBP-4 were greater in high-UIP heifers than low- or mid-UIP heifers on d 12 to 14 of the estrous cycle (P < 0.05). Basal serum LH concentrations and LH area under the curve (every 15 min for 240 min) did not differ (P > 0.10) following 28 d of supplementation (d 10 of the estrous cycle); however, basal serum FSH concentrations were greater (P = 0.06) in low- and mid- vs. high-UIP heifers (5.2 and 5.2 vs. 4.6 ng/mL, respectively), and FSH area under the curve was greater (P = 0.03) in low- vs. high-UIP heifers. At slaughter (d 12 to 14 of the estrous cycle), anterior pituitary LH and FSH content and steady-state mRNA encoding alpha, LHbeta, and GnRH receptor did not differ (P > 0.10) among treatments. However, FSHbeta mRNA was increased approximately twofold (P = 0.03) in mid vs. low UIP. In summary, low and mid levels of UIP supplements fed to estrous cycling beef heifers seemed to enhance pituitary expression and/or secretion of FSH relative to high levels of UIP. Moreover, high-UIP supplementation was associated with increased low-molecular-weight IGFBP compared with supplementation of low and mid levels of UIP. These data suggest that differing levels of UIP supplementation may alter pituitary and ovarian function, thereby influencing reproductive performance in beef heifers.

Regulation of FSHβ and GnRH receptor gene expression in activin receptor II knockout male mice

To examine in vivo, the local effects of inhibins and activins within the anterior pituitary, independent of their endocrine effects exerted from the gonad, in mediating FSH homeostasis, we used castrated knockout mice lacking either inhibin α or activin receptor II (ACVR2) alone or in combination. Compared to castrated wild-type (WT) mice, FSHβ mRNA levels in the pituitaries of Acvr2 null mice were significantly downregulated in the absence of gonadal feedback. FSHβ mRNA levels were not significantly higher in the pituitaries of castrated inhibin α null mice compared to those in Acvr2 null mice and remained the same in the pituitaries of castrated double mutant mice lacking both inhibin and ACVR2. In contrast to FSHβ mRNA expression changes, pituitary FSH content was significantly reduced in Acvr2 null mice whereas it was only slightly upregulated in inhibin α null mice. Combined absence of both ACVR2 signaling and inhibins caused a decrease in FSH content compared to that in the absence of inhibins alone. These changes in pituitary content were in parallel to those in serum FSH levels in these three groups of castrated mice, suggesting that the unopposed actions of locally produced inhibins are dominant over those effects mediated by ACVR2 signaling to regulate FSH biosynthesis and secretion. Thus, our in vivo results demonstrate that within the pituitary, locally produced activins and inhibins exert their actions at distinct phases of FSH homeostasis. In an independent set of experiments, we tested whether in vivo signaling via ACVR2 is necessary for hypothalamic GnRH biosynthesis and for GnRH receptor expression. Our results demonstrate that in contrast to previous in vitro studies, signaling through ACVR2 is neither required for hypothalamic synthesis of GnRH peptide nor for expression of GnRH receptors in the anterior pituitary. We conclude that within the hypothalamic–pituitary short loop, ACVR2 signaling is critical only for FSH homeostasis and not for GnRH biosynthesis or induction of pituitary GnRH receptor expression. Our studies confirm the importance of using in vivo genetic models for studying regulation of the hypothalamic–pituitary–gonadal axis.

Acceleration of maturation of FSH and LH responses to photostimulation in prepubertal domestic hens by oestrogen.

Egg laying begins in domestic hens, reared on short daylengths, at about day 147 of age and is advanced by photostimulation after but not before about day 42 of age. The development of this response at day 42 may be facilitated by oestrogen. This hypothesis was investigated in prepubertal hens, reared on short daylengths, by comparing the effects of oestrogen treatment on pituitary and plasma FSH and LH responses to photostimulation (16 h light:8 h dark) for 1 week at days 34 and 54 of age. Oestradiol benzoate (0.5 mg kg(-1)) was injected i.m. on alternate days for 1 week before and after photostimulation. At day 34, pituitary LH content increased after photostimulation but plasma LH and FSH concentrations did not increase. At day 54, pituitary FSH content and plasma FSH and LH concentrations increased after photostimulation, whereas pituitary LH content did not increase. At days 34 and 54, oestrogen treatment decreased pituitary FSH and LH contents but did not block the stimulatory effect of photostimulation on pituitary FSH. At day 34 but not at day 54, photostimulation combined with oestrogen treatment increased plasma FSH and LH concentrations. Plasma LH but not plasma FSH concentration increased after GnRH-I injection at days 34 and 54. These observations are consistent with the hypothesis that, in prepubertal female chickens, maturation of the neuroendocrine mechanism mediating photoinduced FSH and LH release may be mediated by oestrogen. This effect of oestrogen on photoinduced LH release may be mediated by increased GnRH-I release or enhanced pituitary responsiveness to GnRH-I. It is proposed that neuroendocrine mechanisms controlling photoinduced FSH release may involve oestrogen-responsive interactions between pituitary paracrine factors, including activins and follistatin.

Acceleration of maturation of FSH and LH responses to photostimulation in prepubertal domestic hens by oestrogen

Egg laying begins in domestic hens, reared on short daylengths, at about day 147 of age and is advanced by photostimulation after but not before about day 42 of age. The development of this response at day 42 may be facilitated by oestrogen. This hypothesis was investigated in prepubertal hens, reared on short daylengths, by comparing the effects of oestrogen treatment on pituitary and plasma FSH and LH responses to photostimulation (16 h light:8 h dark) for 1 week at days 34 and 54 of age. Oestradiol benzoate (0.5 mg kg(-1)) was injected i.m. on alternate days for 1 week before and after photostimulation. At day 34, pituitary LH content increased after photostimulation but plasma LH and FSH concentrations did not increase. At day 54, pituitary FSH content and plasma FSH and LH concentrations increased after photostimulation, whereas pituitary LH content did not increase. At days 34 and 54, oestrogen treatment decreased pituitary FSH and LH contents but did not block the stimulatory effect of photostimulation on pituitary FSH. At day 34 but not at day 54, photostimulation combined with oestrogen treatment increased plasma FSH and LH concentrations. Plasma LH but not plasma FSH concentration increased after GnRH-I injection at days 34 and 54. These observations are consistent with the hypothesis that, in prepubertal female chickens, maturation of the neuroendocrine mechanism mediating photoinduced FSH and LH release may be mediated by oestrogen. This effect of oestrogen on photoinduced LH release may be mediated by increased GnRH-I release or enhanced pituitary responsiveness to GnRH-I. It is proposed that neuroendocrine mechanisms controlling photoinduced FSH release may involve oestrogen-responsive interactions between pituitary paracrine factors, including activins and follistatin.